Annals of Oncology Advance Access published online on May 3, 2006
Annals of Oncology, doi:10.1093/annonc/mdl049
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, USA; Current address: Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
* To whom correspondence should be addressed. Background: Approximately one-third of the patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) are cured by second-line chemotherapy followed by high-dose consolidation. The age-adjusted international prognostic index determined at the time of relapse (sAAIPI) predicts outcome in relapsed diffuse large B-cell lymphoma, suggesting that the success of salvage therapy could be enhanced by early relapse detection. This study evaluated the role of surveillance imaging in detection of relapsed disease and its impact on outcome of salvage treatment. Patients and methods: One hundred and eight patients with relapsed aggressive NHL were treated with ICE-based second-line chemotherapy. Relapses were categorized as detected by imaging, examination, or patient-reported symptoms. Results: Twenty per cent of relapses were detected by routine imaging while 80% were identified by reported symptoms or abnormalities on exam. Patients were 4.1 times (95% CI: 1.7-10.2) more likely to have low risk disease if relapse was diagnosed by routine imaging (group 1) compared with those diagnosed by reported symptoms or physical findings (group 2). Median overall 5-year survival for group 1 versus group 2 was 54% and 43% respectively (P = 0.13). Conclusion: These results suggest that routine surveillance imaging can identify a population of patients with a more favorable outcome based on the sAAIPI.
Received October 24, 2005
Revised February 6, 2006
Accepted February 10, 2006
original article
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
M. Liedtke 1,
P. A. Hamlin 2,
C. H. Moskowitz 2,
and
A. D. Zelenetz 2 *
2 Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, USA
A. D. Zelenetz, E-mail: a-zelenetz{at}ski.mskcc.org
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Petrausch, P. Samaras, P. Veit-Haibach, A. Tschopp, J. D. Soyka, A. Knuth, T. F. Hany, A. Mischo, C. Renner, and N. G. Schaefer Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann. Onc., November 13, 2009; (2009) mdp519v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cheson The Case Against Heavy PETing J. Clin. Oncol., April 10, 2009; 27(11): 1742 - 1743. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF]
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage and F. R. Loberiza Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann. Onc., June 1, 2006; 17(6): 883 - 884. [Full Text] [PDF]
|
|